Company Financials: Orthopaedics and Spine

• Posted in Business Critical | August 02, 2012 | Comments (0)
• Tags: earnings, financial, company financials, sales
• By: Julie A. Vetalice

ORTHOWORLD’s estimates place overall 1Q12 market growth at 4% over 1Q11, as shown in Exhibit 1. Performance highlights follow and pertain to 1Q12, unless noted otherwise.

Exhibit 1: Orthopaedic Sales Increases¹ by Product Segment: 1Q12 vs. 1Q11

NOTES TO EXHIBIT 1

1. Orthopaedic products; constant currency, pro forma growth
2. Includes biologics
3. For the quarter ended 2/29/12; includes Dental. Spine includes Bone Stim and Biologics; Bone Stim reflects all Bone Healing sales.
4. For the quarter ended 4/27/12
5. Spine
6. For the quarter ended 3/31/12
7. Extremities: extremities + fixation combined; Endoscopy: endoscopic + communications, most of which is orthopaedic; Spine: neuro + spine. Total growth excludes Patient Handling.
8. ORTHOWORLD estimates
9. For the quarter ended 3/31/12